⌕
Structure Therapeutics · GPCR · Nasdaq
Tenet — · insufficient data
Compare
$18.17−2.15%Market open
$18.17−0.40 (−2.15%)
Market open · 15-min delayed · as of 3:48 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Structure Therapeutics (GPCR) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is GPCR's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Zacks Investment ResearchNov 13, 2026 · 10:16 ET
4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day

LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.…

GPCR −2.2% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028 Additional aleniglipron data expected in Q4 20…

GPCR −2.2% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference

SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, wit…

GPCR −2.2% todayRead at source ↗
● Defense WorldOct 21, 2026 · 04:15 ET
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Has Consensus Price Target of $110.91 According to Brokerages

Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the sixteen ratings firms that are presently covering the stock, Marketbeat reports. One inv…

GPCR −2.2% todayRead at source ↗
● GlobeNewsWireOct 19, 2026 · 16:13 ETCOMPANY'S OWN WORDS
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026

SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, wit…

GPCR −2.2% todayRead at source ↗
● Defense WorldOct 16, 2026 · 03:41 ET
Structure Therapeutics (NASDAQ:GPCR) Sets New 52-Week Low – Here’s Why

Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR - Get Free Report) hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as $22.10 and last traded at $22.31, with a volume of 1,434,…

GPCR −2.2% todayRead at source ↗
● Defense WorldSep 26, 2026 · 04:15 ET
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR - Get Free Report) have received an average recommendation of "Moderate Buy" from the seventeen research firms that are presently covering the stock, Mark…

GPCR −2.2% todayRead at source ↗
● Seeking AlphaSep 16, 2026 · 14:31 ET
Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

GPCR −2.2% todayRead at source ↗
● Seeking AlphaSep 9, 2026 · 13:16 ET
Structure Therapeutics: The Amylin Data Changes The Math

Structure Therapeutics remains a Strong Buy, with recent data de-risking its lead oral obesity drug, aleniglipron. Aleniglipron's 72-week open-label data showed 16.2% weight loss, low AE discontinuations, and no DILI, th…

GPCR −2.2% todayRead at source ↗
● Seeking AlphaSep 8, 2026 · 18:45 ET
Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript

Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript…

GPCR −2.2% todayRead at source ↗
● GlobeNewsWireSep 8, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial…

GPCR −2.2% todayRead at source ↗
● GlobeNewsWireSep 3, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, wi…

GPCR −2.2% todayRead at source ↗
● Seeking AlphaAug 28, 2026 · 18:00 ET
Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term

Septerna, Inc. has surged >315% since May 2025, driven by its GPCR-focused drug discovery and a high-profile collaboration with Novo Nordisk. The SEPT partnership with NOVO targets GLP-1, GIP, and glucagon receptors, wit…

GPCR −2.2% todayRead at source ↗
● Zacks Investment ResearchAug 26, 2026 · 09:21 ET
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?

Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.…

GPCR −2.2% todayRead at source ↗
● Seeking AlphaAug 21, 2026 · 14:21 ET
Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030

Structure Therapeutics (GPCR) maintains a Buy rating, driven by strong Phase 2b data for its oral GLP-1 candidate aleniglipron targeting obesity. Aleniglipron demonstrated up to 16.2% weight loss at 44 weeks, a favorable…

GPCR −2.2% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA18−1.7%
GOOG6−1.5%
AMD3−2.9%

Article counts from the last market-wide feed page, across every symbol we track and not just GPCR · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.